A peripheral diagnostic biomarker for Major Depressive Disorder

重度抑郁症的外周诊断生物标志物

• 批准号: 8730225
• 负责人: Lee E Schechter
• 金额: $ 34.95万
• 依托单位: PAX NEUROSCIENCE, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-04 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8730225
• 关键词: Address; Adenylate Cyclase; Animal Model; Antidepressive Agents; Anxiety Disorders; Area; Biological; Biological Assay; Biological Markers; Bipolar Disorder; Blood Cells; Blood Platelets; Caring; Chronic; Clinical; Clinical Trials; Clinical assessments; Cost Savings; Coupling; Cyclic AMP; Data; Depressed mood; Detection; Developed Countries; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Diagnostic tests; Disease; Disease remission; Early treatment; Enrollment; Erythrocytes; Event; Expenditure; Feasibility Studies; Future; GTP-Binding Proteins; Goals; Healthcare; Heart Diseases; Incentives; Individual; Institutes; Insurance Carriers; Leukocytes; Location; Major Depressive Disorder; Marketing; Measures; Medical; Medical Economics; Membrane; Membrane Microdomains; Mental Depression; Mood Disorders; Motivation; Neurosciences; Outcome; Patients; Peripheral; Pharmacologic Substance; Phase; Population; Psychiatric therapeutic procedure; Public Health; Recruitment Activity; Research; Sampling; Services; Signal Transduction; Signaling Protein; Small Business Innovation Research Grant; Symptoms; Testing; Time; Venous blood sampling; Visit; Work; World Health Organization; base; cell type; cost; depressive symptoms; diagnostic accuracy; disability; drug discovery; improved; innovation; primary care setting; public health relevance; social; social stigma; tool; treatment response

DESCRIPTION (provided by applicant): The World Health Organization estimates that by 2020 major depressive disorder (MDD) will be the most common cause of disability worldwide. The medical and non-medical costs of MDD in the US exceed $80 billion annually. Although approximately 1 in 6Americans will suffer from MDD during their lifetime, roughly half of all patients with MDD go undiagnosed in primary care settings, and another fifth are incorrectly diagnosed as having MDD when they in fact have another psychiatric illness. Given the substantial medical, economic and social costs incurred when MDD is undiagnosed or untreated, there is tremendous need for a simple office- based biomarker test to aid clinicians in accurately identifying MDD. For a psychiatric diagnostic test to have clinical value, it must reliably distinguish not only between MDD and healthy individuals, but also between MDD and other significant Axis I disorders (e.g. bipolar disorder or anxiety disorders) that may present with symptoms that could be mistaken for MDD. No test currently exists that can accurately diagnose MDD and distinguish it from other psychiatric conditions. The potential market for an accurate diagnostic test for MDD is very large. Payers of medical services would cover the cost of such a diagnostic test because accurately identifying and treating MDD would reduce the high medical costs arising from medical service delivery to patients with untreated depression, as well as improving outcomes for patients with comorbid medical conditions such as diabetes or heart disease. Another market for an MDD diagnostic test are pharmaceutical companies. These companies have uniformly retreated from discovery efforts in mood disorders, in part due to the high rate of failed clinical trials, thought to arise in part from enrollment of inappropriae patients. An objective test of MDD could address this concern by providing certainty about the appropriateness of recruited patients, thereby enhancing confidence that trial results accurately reflect the true efficacy (or inefficacy) of investigated compounds. The Pax Neuroscience diagnostic biomarker Gsa Sequestration Assay (GSA), measures the localization of Gs¿, a crucial G protein that activates adenylyl cyclase to produce cyclic adenosine monophosphate (cAMP) and initiate downstream events. Gs¿ shuttles between a state of sequestration in lipid rafts (relatively inactive), and a non-lipid raft location where it is freer to activate adenylyl cyclase. The Pax Neuroscience GSA biomarker measures the ratio of Gs¿ between those states. Our preliminary data indicate that MDD patients have a significantly greater proportion of Gs¿ captured in lipid rafts compared to non-depressed controls, which is consistent with other research indicating disrupted function of Gs¿, adenylyl cyclase and cAMP in MDD patients. These findings suggest the Pax Neuroscience GSA biomarker can accurately identify patients suffering from MDD. The proposed study will test the hypothesis that the ratio of Gs¿ in and out of lipid rafts is an accurate and specific biomarker for MDD diagnostic purposes.

描述（由申请人提供）：世界卫生组织估计，到2020年，重度抑郁症（MDD）将成为全球最常见的残疾原因。在美国，MDD的医疗和非医疗费用每年超过800亿美元。虽然大约1/6的美国人在一生中会遭受MDD的折磨，但大约一半的MDD患者在初级保健环境中未被诊断出来，另外五分之一的人被错误地诊断为患有MDD，而实际上他们患有另一种精神疾病。考虑到MDD未被诊断或未治疗时产生的大量医疗、经济和社会成本，非常需要一种简单的基于办公室的生物标志物测试来帮助临床医生准确识别MDD。精神病诊断测试要具有临床价值，不仅必须可靠地区分MDD和健康个体，而且还必须区分MDD和其他可能出现可能被误认为MDD的症状的重要轴I障碍（例如双相情感障碍或焦虑症）。目前还没有测试可以准确诊断MDD并将其与其他精神疾病区分开来。MDD的准确诊断测试的潜在市场非常大。医疗服务的支付者将支付这种诊断测试的费用，因为准确识别和治疗MDD将减少向未经治疗的抑郁症患者提供医疗服务所产生的高昂医疗费用，并改善患有糖尿病或心脏病等合并症的患者的结果。MDD诊断测试的另一个市场是制药公司。这些公司一致从情绪障碍的发现努力中撤退，部分原因是临床试验失败率高，部分原因是招募了不适当的患者。MDD的客观测试可以通过提供招募患者的适当性的确定性来解决这一问题，从而增强试验结果准确反映所研究化合物的真实有效性（或无效性）的信心。Pax神经科学诊断生物标志物Gsa螯合测定（GSA）测量Gs的定位，Gs是一种关键的G蛋白，其激活腺苷酸环化酶以产生环磷酸腺苷（cAMP）并启动下游事件。格斯在脂质筏中的隔离状态（相对无活性）和更自由地激活腺苷酸环化酶的非脂质筏位置之间穿梭。Pax Neuroscience GSA生物标志物测量了这些状态之间的Gs的比例。我们的初步数据表明，与非抑郁对照组相比，MDD患者在脂筏中捕获的Gs <$比例显著更大，这与其他研究表明MDD患者Gs <$、腺苷酸环化酶和cAMP功能受损一致。这些发现表明Pax Neuroscience GSA生物标志物可以准确识别患有MDD的患者。拟议的研究将检验以下假设：脂筏内外的Gs？比值是MDD诊断目的的准确和特异性生物标志物。